london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Central retinal artery occlusion with thrombocytosis and JAK 2 kinase mutation

Poster Details

First Author: R.Singh UK

Co Author(s):    V.J. Menon                  0   0 0   0 0   0 0   0 0

Abstract Details


Case report of Central Retinal Artery Occlusion (CRAO) with thrombocytosis and a Janus Kinase 2 (JAK 2) mutation V617F. A novel association which has not previously been reported. Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signalling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family (IL-3R, IL-5R and GM-CSF-R), the gp130 receptor family (e.g., IL-6R), and the single chain receptors. Reports have suggested that JAK2 signalling causes increased permeability of the Retinal Pigment Epithelium


Department of Ophthalmology, Kettering General Hospital NHS Foundation Trust, Kettering NN16 8UZ, UK (Affiliated Teaching Hospital, University of Leicester)


A 52 year old male presented to the Eye Casualty with a sudden loss of vision in the left eye associated with pain. The vision in the left eye was light perception only and the vision in the right eye was normal (6/5). No scalp tenderness and jaw claudication was reported. A clinical diagnosis of Central Retinal Artery Occlusion (CRAO) left eye was made and bloods and temporal biopsy was ordered. Patient was referred to the vascular team and started on oral steroids


Blood test revealed a significant thrombocytosis 689 (150-450 normal). ESR, CRP were normal. Temporal Artery Biopsy did not reveal any significant pathological changes. Carotid Doppler did reveal an occluded Internal Carotid Artery on the affected side (left). A significant finding was a mutation in the Janus 2 Kinase (JAK2) V617F, a test advised by the hematology. The patient was started on oral Aspirin (75 mg) and oral steroids which were gradually tapered off. The vision of patient improved to 3/60 in the affected eye (left) in six weeks


This case report is to demonstrate a novel association of JAK2 mutation with Central Retinal Artery Occlusion and a further research in the subject is required

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy